Considerations for widespread implementation of blood‐based biomarkers of Alzheimer's disease.

MLA

Mielke, Michelle M., et al. “Considerations for Widespread Implementation of Blood‐based Biomarkers of Alzheimer’s Disease.” Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, vol. 20, no. 11, Nov. 2024, pp. 8209–15. EBSCOhost, https://doi.org/10.1002/alz.14150.

APA

Mielke, M. M., Anderson, M., Ashford, J. W., Jeromin, A., Lin, P., Rosen, A., Tyrone, J., VandeVrede, L., Willis, D., Hansson, O., Khachaturian, A. S., Schindler, S. E., Weiss, J., Batrla, R., Bozeat, S., Dwyer, J. R., Holzapfel, D., Jones, D. R., Murray, J. F., & Partrick, K. A. (2024). Considerations for widespread implementation of blood‐based biomarkers of Alzheimer’s disease. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 20(11), 8209–8215. https://doi.org/10.1002/alz.14150

Chicago

Mielke, Michelle M., Matthew Anderson, J. Wesson Ashford, Andreas Jeromin, Pei‐Jung Lin, Allyson Rosen, Jamie Tyrone, et al. 2024. “Considerations for Widespread Implementation of Blood‐based Biomarkers of Alzheimer’s Disease.” Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 20 (11): 8209–15. doi:10.1002/alz.14150.